Regeneron to pay Sanofi up to $1.1 billion plus royalties for its stake in Libtayo collaborationMarket Watch • 06/02/22
Press Release: Sanofi grants Regeneron worldwide exclusive license rights to Libtayo® (cemiplimab)GlobeNewsWire • 06/02/22
FDA gives Sanofi's experimental hemophilia A drug a Breakthrough Therapy designationMarket Watch • 06/01/22
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)Zacks Investment Research • 05/25/22
Sanofi SA (SNY) CEO Paul Hudson on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 04/28/22
Press Release: Sanofi continues to deliver strong business EPS growth driven by higher sales and improved margins in Q1GlobeNewsWire • 04/28/22